Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

1 Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and

2 Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses

3

than that of the Partially Effective gB/MF59 Vaccine

Running Title: Broad and functional HCMV-specific IgG responses elicited by mRNA-1647 in
 humans.

- 6 Xintao Hu¹[§], Krithika P. Karthigeyan¹[§], Savannah Herbek¹, Sarah M. Valencia², Jennifer A. Jenks²,
- 7 Helen Webster², Itzayana G. Miller¹, Megan Connors¹, Justin Pollara², Caroline Andy³, Linda M.
- 8 Gerber³, Emmanuel B. Walter², Kathryn M. Edwards⁴, David I. Bernstein⁵, Jacob Hou⁶, Matthew
- 9 Koch⁶, Lori Panther⁶, Andrea Carfi⁶, Kai Wu⁶, Sallie R. Permar^{1*}
- 10
- ¹Weill Cornell Department of Pediatrics, New York, NY 10065
- ¹² ²Duke Human Vaccine Institute, Duke University Medical Center, Durham, UN 27710
- ¹³ ³Weill Cornell Department of Population Health Sciences, New York, NY 10065
- ⁴Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232
- ⁵Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati,
- 16 Cincinnati, OH 45229
- ⁶Moderna, Inc., Cambridge, MA 02139
- 18
- 19 Xintao Hu: xih4005@med.cornell.edu
- 20 Krithika P. Karthigeyan: kpk4001@med.cornell.edu
- 21 Savannah Herbek: sah4019@med.cornell.edu
- 22 Sarah M. Valencia: sarah.valencia@duke.edu
- 23 Jennifer A. Jenks: jennifer.jenks@duke.edu
- 24 Helen Webster: helen.webster12@gmail.com
- 25 Itzayana G. Miller: igm4001@med.cornell.edu
- 26 Megan Connors: mec4016@med.cornell.edu
- 27 Justin Pollara: jpollara@duke.edu
- 28 Caroline Andy: cma2008@med.cornell.edu
- 29 Linda M. Gerber: lig2002@med.cornell.edu
- 30 Emmanuel B. Walter: chip.walter@duke.edu
- 31 Kathryn M. Edwards: kathryn.edwards@vumc.org
- 32 David I. Bernstein: David.Bernstein@cchmc.org
- 33 Jacob Hou: Jacob.Hou@modernatx.com
- 34 Matthew Koch: Matthew.Koch@modernatx.com
- 35 Lori Panther: Lori.Panther@modernatx.com
- 36 Andrea Carfi: Andrea.Carfi@modernatx.com
- 37 Kai Wu: Kai.Wu@modernatx.com
- 38 [§]equal contribution to this manuscript
- ^{*}Corresponding author: Sallie R. Permar, M.D., Ph.D., Phone: +1 212 746 4111; Email:
- 40 sap4017@med.cornell.edu
- 41
- 42

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

43 Summary

- 44 mRNA-1647 HCMV vaccine elicited polyfunctional and durable antibody responses in humans.
- 45 While the mRNA-1647-elicited glycoprotein B (gB)-specific IgG responses were lower than that
- 46 of the moderately-effective gB/MF59 vaccine, the pentameric complex (PC)-specific IgG
- 47 responses were strong.

- . .

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript submissiondraft

64 **ABSTRACT**

Background. The MF59-adjuvanted gB subunit (gB/MF59) vaccine demonstrated ~50% efficacy against human cytomegalovirus (HCMV) acquisition in multiple clinical trials, suggesting efforts to improve this vaccine design might yield a vaccine suitable for licensure. A vaccine candidate employing nucleoside-modified mRNAs encoding HCMV gB and pentameric complex (PC) encapsulated in lipid nanoparticle, mRNA-1647, is currently in late-stage efficacy trials. Yet, its immunogenicity has not been compared to the partially-effective gB/MF59 vaccine.

Methods. We assessed neutralizing and Fc-mediated IgG effector antibody responses induced by mRNA-1647, a vaccine comprising an equal mass of 6 mRNAs encoding gB and PC antigens, in both HCMV seropositive and seronegative vaccinees from a first-in-human clinical trial through 1-year following 3rd vaccination using a systems serology approach. Further, we compared peak anti-gB antibody responses in seronegative mRNA-1647 vaccinees to that of seronegative female adolescent gB/MF59 vaccine recipients.

Results. mRNA-1647 vaccination boosted pre-existing HCMV-specific IgG responses in seropositive vaccinees, including neutralizing and Fc-mediated effector antibody responses. In seronegative vaccinees, mRNA-1647 induced durable and functional HCMV-specific IgG responses. Elicited gB-specific IgG responses were lower than the PC-specific IgG responses. Additionally, gB-specific IgG and antibody-dependent cellular phagocytosis (ADCP) responses were lower than those elicited by gB/MF59. However, mRNA-1647 elicited robust neutralization and high antibody-dependent cellular cytotoxicity (ADCC) responses.

Conclusions. mRNA-1647 vaccination induced polyfunctional and durable HCMV-specific
 antibody responses. mRNA-1647-elicited gB-specific IgG responses were lower than PC-specific
 IgG responses and lower than those elicited by the partially effective gB/MF59. However, higher
 neutralization and ADCC responses were elicited by mRNA-1647 than gB/MF59.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

88	Clinical	Trials	Registration.	ClinicalTrials.gov	(NCT03382405,	mRNA-1647)	and				
89	(NCT00133497, gB/MF59).										
90	Keywords. human cytomegalovirus; mRNA-1647 vaccine; pentametric complex (PC); durability;										
91	gB/MF59	vaccine.									
92											
93											
94											
95											
96											
97											
98											
99											
100											
101											
102											
103											
104											
105											
106											
107											
108											

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

109 INTRODUCTION

Human cytomegalovirus (HCMV), a ubiquitous herpes virus, leads to life-threatening diseases in 110 111 newborns infected in utero (1) and in immunocompromised individuals (2), with severe symptoms such as enteritis, pneumonitis, and neurologic deficits (1, 2), highlighting the need for an effective 112 113 vaccine to prevent infection and disease (3, 4). Viral attachment is mediated by major envelope 114 glycoprotein complexes on the virion surface (3, 5), including glycoprotein B (gB), the primary viral fusion protein (6), and gH/gL/UL128/UL130/UL131A pentametric complex (PC), which is 115 essential for entry into epithelial, endothelial, dendritic, and monocytic cells (7). Both gB and PC 116 117 are viable targets for antibody based anti-CMV interventions (3, 8).

MF59-adjuvanted HCMV Towne gB subunit vaccine (gB/MF59) is the most efficacious HCMV vaccine tested to date, with approximately 50% protection in several phase 2 trials (9-12). Yet, efficacy was not high enough to advance to late-stage clinical trials. Therefore, efforts are needed to develop a better vaccine that elicits more protective responses. Interestingly, this vaccine achieved moderate protection with only limited neutralizing antibody (NAb) responses, suggesting a role for non-NAb responses in preventing HCMV acquisition (9, 13, 14). However, inducing broad and potent NAb responses might also enhance vaccine efficacy (3).

125 Frequent reinfection and reactivation in HCMV-exposed individuals represent another challenge 126 to preventing and controlling disease (15). Vaccination may enhance immunity to prevent reinfection or end-organ disease in affected populations (3). Although the precise immune 127 correlates of protection against HCMV acquisition, congenital HCMV (cCMV) transmission, or 128 end-organ disease have yet to be established, there is growing evidence that Fc-mediated 129 130 effector antibody functions are important in preventing cCMV transmission (16, 17). Adding antigens that induce potent NAb and Fc-mediated effector responses might elicit polyfunctional 131 humoral responses that improve vaccine efficacy (3, 8). 132

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

133 The modified mRNA encapsulated in lipid nanoparticle (LNP) vaccine platform has remarkable 134 advantages for both manufacturing ease and safe induction of effective immunity in humans (3, 18). Toward this end, Moderna developed an HCMV vaccine candidate, mRNA-1647, comprised 135 of both gB and PC (19, 20), which induced durable and functional antibody responses in 136 137 preclinical studies in mice and non-human primates (NHP) (19, 20). In this report, we comprehensively assessed the polyfunctional humoral responses elicited by mRNA-1647 in 138 HCMV seronegative and seropositive vaccinees and compare the gB-specific IgG responses with 139 those induced by the partially effective gB/MF59 vaccine. 140

141 METHODS

142 Study Participants and Design

Information about study participants is summarized in Table 1. Both gB/MF59 and mRNA-1647 vaccines were delivered via intramuscular injection (IM) in a three-dose series at months 0, 1 or 2 and 6 (Figure 1A). gB/MF59 samples came from a Phase 2 study in healthy adolescent females (NCT00133497). mRNA-1647 samples are from a Phase 1 study in healthy adults (NCT03382405). Information about study products and design is detailed in supplementary materials.

149 **IgG Binding Assays**

Sera IgG binding to HCMV TB40/E virions, Towne gB, Towne gB AD2S1 peptide and VR1814 PC was measured by ELISA as previously described (9, 16, 21). Sera IgG binding to gB expressed on the cell surface was measured by flow cytometry as previously described (9, 16, 21). IgG and subclasses IgG1, IgG2, IgG3 binding to HCMV antigens (gB, gB AD-1, gB AD4, gB AD5, gB AD4+AD5, PC) and Fcγ receptors (FcγR1A, FcγR2A, FcγR2B, FcγR3A) and neonatal receptor (FcRN) were measured by binding antibody multiplex assay (BAMA) as described (9, 16,

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

156 21). Results were acquired on a Bio-Plex 200 system (Bio-Rad) and reported as mean 157 fluorescence intensity (MFI).

158 Functional Ab Assays

Neutralization was measured by employing HCMV immediate early-1 (IE-1) gene expression to 159 160 quantify reduction in virus infection in fibroblast HFF-1 or epithelial ARPE-19 cells (9, 16, 21). 161 ID₅₀s were calculated using non-linear regression analysis (Sigmoidal, 4PL) using GraphPad 162 Prism. ADCC was measured using cell-surface expression of CD107a as a marker for NK cell degranulation, as described (16, 21). Primary human NK cells were incubated with AD169-163 derivative BadrUL131-Y4/GFP-infected MRC-5 cell monolayers (22). The frequencies of 164 165 CD107a+ live NK cells were determined by flow cytometry. For ADCP assays, an optimized amount of AD169r virions (1x10³ PFU/well) was conjugated to AF647 NHS ester before incubation 166 167 with diluted sera (1:100). Virus-antibody immune complexes were spinoculated and incubated 168 with THP-1 cells and stained with Agua Live/Dead dye, and the percentage of AF647+ cells was 169 reported for each sample based on the live, singlet population.

170 **RESULTS**

171 mRNA-1647 vaccination elicited durable HCMV-specific IgG responses

HCMV gB- specific IgG responses were significantly increased above baseline at seven months 172 post-vaccination (peak timepoint) in seronegative vaccinees and elevated in seropositive 173 174 vaccinees (Figure 1B, 1C). Similarly, PC-specific peak IgG responses were also significantly increased at month 7 in seronegative vaccinees and elevated in seropositive vaccinees (Figure 175 1D,1E). Peak gB-specific IgG responses in seronegative vaccinees were comparable to 176 177 responses induced by natural infection, whereas PC-specific IgG responses were 10-fold higher 178 than those induced by natural infection (Figure S2A-S1B). Peak gB- and PC-specific (Figure S3A-3F) IgG1, IgG2, and IgG3 responses were elicited in seronegative vaccinees, while only IgG1 179

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

180 responses were elevated above baseline in seropositive vaccinees (Figure S3A, 3D). gB- and 181 PC-specific IgG responses persisted through one year after the last vaccination in seronegative vaccinees (Figure 1B, D). While IgG responses declined between month 7 to 12, no significant 182 change was observed in vaccine-elicited IgG levels between month 12 to 18 (Figure 1B-1E). 183 184 Interestingly, the relative avidity index (RAI) for gB-specific IgG declined significantly between month 7 and 12 only in seronegative vaccinees (Figure S4A-S4B). In contrast, PC-specific IgG 185 maintained an equivalent RAI at both month 12 and 18 relative to month 7 in seronegative and 186 187 seropositive vaccinees (Figure S4C-S4D).

Significant increases in HCMV-binding IgG levels against TB40/E (gB1 genotype) (21) were observed in seronegative, but not seropositive individuals, after vaccination (Figure 1F, 1G), though this was significantly lower than those elicited by natural infection (Figure S2C). Virionbinding IgG responses in seronegative vaccinees declined in magnitude (Figure 1F), but not in avidity (Figure S4E), between months 7 and 12 and returned to baseline by month 18. In seropositive vaccinees, there was no change in magnitude or avidity of virion-binding IgG after vaccination (Figure 1G, Figure S4F),

195 IgG binding to gB-transfected cells was previously identified as a correlate of protection against HCMV acquisition in the gB/MF59 vaccine trials (9). Thus, we measured IgG binding to mRNA-196 197 1647 vaccine strain-matched Merlin and heterologous gB1 genotype (Towne) gB-transfected cells for both vaccine populations. IgG responses to cell-associated Merlin and Towne gB were 198 elicited in seronegative vaccinees (Figure 1H; Figure S5), and Merlin gB-transfected IgG binding 199 200 responses remained high one year after the last vaccination. Only Towne cell-associated gB 201 responses were significantly increased by vaccination in seropositive vaccinees (Figure 1I; Figure S5), demonstrating that mRNA-1647 was able to elicit broad IgG responses and boost pre-202 existing responses against the cell-associated conformation of gB. 203

204 mRNA-1647 induced broad and long-lasting NAb responses

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

205 We measured NAb responses against homologous (Towne, gB1) and heterologous (AD169r, gB2) 206 gB genotype strains in fibroblasts and epithelial cells. Low level fibroblast NAb responses against Towne (Figure 2A, 2B) and AD169r (Figure 2C, 2D) were elicited by month 7 after vaccination in 207 seronegative mRNA-1647 vaccinees and were increased above baseline in seropositive 208 209 vaccinees . In contrast, mRNA-1647 elicited potent epithelial NAb responses against AD169r in 210 seronegative vaccinees at month 7 after vaccination, and >400-fold above the fibroblast neutralization titer (median ID50 40660 vs. 99). These responses were durable through one year 211 212 after the last vaccination (Figure 2E). The magnitude of vaccine-elicited epithelial, but not 213 fibroblast, NAb responses was significantly higher than those induced by natural infection (Figure S6A-S6C). This response was also increased by 55-fold compared to pre-existing responses in 214 seropositive vaccinees and maintained through one year after the final vaccination (Figure 2F). 215

IgG responses against gB antigenic domains (AD) were detectable against AD4, and AD4&AD5 (Figure S7B, S7D) in seronegative vaccinees at month 7 after mRNA-1647 vaccination, revealing an AD4 dominant IgG response that did not correlate with fibroblast NAb responses. In seropositive vaccinees, anti-AD4, AD4&D5, and AD2S1 responses were boosted by vaccination (Figure S7B, S7D-S7E), and these responses also did not correlate with fibroblast NAb responses. However, nAb responses against AD169r correlated strongly with AD4, AD4&AD5-specific IgG binding when seronegative and seropositive vaccinee responses were combined (Table S1).

223 mRNA-1647 elicited Fc-mediated functional antibody responses

We next evaluated vaccine-induced antigen-specific Fc-mediated IgG responses. In all vaccinees, we found significant increases in both gB- and PC-specific (Figure 3A, 3B) IgG responses that bound to all tested FcRs (FcγR1A, FcγR2A, FcγR2B, FcγR3A and FcRN). Both ADCC and ADCP responses were significantly increased in seronegative vaccinees following vaccination but not in seropositive vaccinees (Figure 3C, 3D). ADCC and ADCP responses in seropositive vaccinees at baseline were significantly higher than peak responses for seronegative vaccines, suggesting

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

230 that these responses are more potently elicited by infection than vaccination. AD169r virion-231 specific ADCC strongly correlated with all tested gB-specific, but not PC-specific, FcR-binding IgG levels in seronegative vaccinees (Table S2; Figure 3E-3F). When our analysis was expanded 232 to the total vaccinated population, we observed strong correlation between ADCC and gB-specific 233 234 FcR-binding IgG levels; particularly, gB-specific $Fc\gamma R3A$ -binding (Figure 3F, r = 0.87, p < 0.001), which is expressed on NK cells that mediate ADCC (23). Similarly, we observed positive 235 correlation between AD169r virion-specific ADCP response and all evaluated gB- and PC-specific 236 237 IgG FcR binding responses levels in seronegative vaccinees, and the correlation became stronger 238 when the analysis was extended to the total vaccinated population (Table S2: Figure 3G-3H), in particular for gB-specific Fc γ R1A (r = 0.93, p < 0.001) and Fc γ R2A (r = 0.93, p < 0.001) (Figure 239 240 3H).

241 mRNA-1647 induced higher PC- than gB-specific IgG responses

To evaluate if balanced humoral responses were induced for both antigens encoded by the mRNA-1647 formulation, we compared vaccine-elicited PC- and gB-specific IgG responses. We found significantly higher PC- than gB-specific IgG responses in seronegative vaccines, including total IgG, IgG1, and IgG3 (Figure 4A - 4D) responses. There was a trend towards higher PC- than gB-specific total IgG and IgG1 responses in seropositive vaccinees, but only PC-specific IgG3 responses were significantly higher (Figure 4E, 4F and 4H).

PC-specific FcR-binding IgG responses were also higher in seronegative vaccinees compared to gB-specific responses (Figure 4I-4M); which was also observed when data was normalized to gBand PC-specific IgG levels, (Figure S8) with the exception of FcγR1A binding. Further, PC-specific FcγR3A-binding IgG responses also trended higher than gB-specific responses in seropositive vaccinees (Figure 4Q). This difference may be underestimated as the PC-specific, but not gBspecific, responses were at the maximum limit of detection (Figure 4Q). Although no significant

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript submissiondraft

difference was found for $Fc\gamma R1A$, 2A and 2B IgG binding between PC-specific and gB-specific IgG responses in seropositive vaccinees, these responses were also at the maximum limit of detection (Figure 4N-4Q). FcRN-binding IgG responses that were PC-specific were elicited by month 7 in seropositive vaccinees (Figure 4R).

258 mRNA-1647 elicited broad and potent NAb and higher ADCC responses, but lower gB-

259 specific IgG and ADCP responses compared to gB/MF59 in seronegative vaccinees

260 We compared peak gB-specific IgG responses in HCMV-seronegative vaccinees at month 7 post-261 vaccination among two vaccine cohorts. The vaccines were delivered intramuscularly on a similar 262 schedule, and included a gB1 genotype antigen (Figure 5A), gB/MF59 vaccine induced significantly higher gB-specific IgG responses compared to the mRNA-1647 vaccine, yet with 263 similar avidity (Figure 5B, 5C). Vaccine-induced gB-specific IgG subclass responses, including 264 265 IgG1 and IgG3 (Figure 5D - 5F), were also significantly elevated in the gB/MF59 vaccine cohort, in which total IgG and IgG1 was higher than that induced by natural infection (Figure 5B, 5D). 266 Interestingly, ratios of aB-specific IgG2/IgG1 and IgG3/IgG1 were higher in the mRNA-1647 vs 267 268 gB/MF59 vaccine cohort (Figure 5E-5F) suggesting distinct vaccine-induced IgG subclass 269 patterns. Despite the inclusion of 2 major glycoprotein complexes in mRNA-1647, gB/MF59 vaccination elicited higher virion-binding IgG against TB40/E in terms of both magnitude (Figure 270 5G) and avidity (Figure 5H). 271

272 gB/MF59 immunization also elicited higher cell-associated autologous Towne gB-specific IgG 273 responses than the mRNA-1647 vaccine (Figure 5I). IgG against cell-associated Merlin gB (Figure 274 5J) that trended higher in the gB/MF59 cohort than that induced by mRNA-1647. Finally, no 275 difference in gB AD-specific IgG responses was found among gB/MF59 and mRNA-1647 vaccine 276 cohorts (Figure S9A-S9E, Table 2).

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

277 Despite the lower gB-specific IgG responses compared to those elicited by gB/MF59. mRNA-278 1647 vaccine induced higher heterologous virus (AD169r) NAb responses in both epithelial (Figure 5K) and fibroblast (Figure 5L) cells, including fibroblast NAb responses against the 279 gB/MF59 homologous Towne virus (Figure 5M), indicating that mRNA-1647 vaccine-induced PC-280 281 specific antibody responses may contribute to the fibroblast-tropic NAb responses (24). 282 Additionally, the gB/MF59 vaccine induced higher gB-specific IgG FcyR2A, 2B, 3A and FcRN 283 binding responses compared to that of mRNA-1647, yet similar levels of binding to FcyR1A 284 (Figure 6A – 6E). When normalized to gB-specific IgG responses, the gB/MF59 vaccinees still 285 had higher FcyR2B, 3A, and FcRN, but lower FcyR1A (Figure S10C- S10E and S10A), binding responses (Figure S10B). Finally, mRNA-1647 vaccine induced higher ADCC, vet lower ADCP 286 (Figure 6F, 6G) responses compared to the gB/MF59 vaccine. No significant correlation was 287 288 found between tested FcR binding and ADCC/ADCP responses in the gB/MF59 cohort (Table S3). The humoral response comparison between the vaccine cohorts is summarized in Table 2. 289

290 **DISCUSSION**

In this report, we demonstrate that mRNA-1647 HCMV vaccine induced potent and durable HCMV-specific IgG responses in seronegative participants in a first-in-human vaccine trial, mirroring preclinical immunogenicity results (19, 20). It also boosted pre-existing HCMV-specific IgG responses in seropositive vaccinees. mRNA-1647 elicited broad and potent neutralization as well as Fc-mediated effector functions, including robust ADCC responses. These features support its advancement into ongoing late-stage clinical trial assessing its efficacy for prevention of HCMV acquisition in seronegative women.

Humoral immune correlates of protection against HCMV acquisition or vertical transmission are still being investigated (8); hence broad and polyfunctional humoral immunity is desirable. Interestingly, gB-specific IgG responses in mRNA-1647 vaccinees was considerably lower than

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

301 that of the PC-specific IgG response and that elicited by the gB/MF59 vaccine, indicating potential 302 room for improvement of the immunogenicity of the gB antigen. The lower magnitude of gB vs PC-specific IgG responses could be in part be due to the lower total amount of gB vs PC mRNA 303 in the vaccine formulation (gB vs. PC: 30µg vs.150µg), suggesting re-formulation of the vaccine 304 305 could lead to more balanced responses. Alternative approaches could combine mRNA and protein antigens in a co-delivery strategy, similar to that applied other vaccine platforms (28, 29). 306 Of note, PC was recently shown to be dispensable for cCMV transmission in NHPs (25); yet, the 307 308 impact of the addition of PC to an HCMV vaccine on efficacy is yet unclear, but will be informed 309 by the ongoing mRNA-1647 trial.

While neutralization responses were absent or minimal in gB/MF59 vaccinees, the PC-specific 310 311 IgG and neutralization responses elicited by mRNA-1647 were quite robust (Table 2). Yet, the 312 magnitude of gB-specific IgG responses elicited by mRNA-1647, assayed against the 313 heterologous Towne gB protein, were significantly lower than that elicited by the gB/MF59 vaccine. The elicited IgG binding to cell-associated Towne gB, the immune correlate of protection in the 314 gB/MF59 vaccine trials (9), was also lower in the mRNA-1647 group. However, IgG binding to 315 cell-associated Merlin gB, which is strain matched to the mRNA-1647 vaccine, was equivalent 316 317 among the vaccinees (Figure 5J). Further, ADCC responses elicited by mRNA-1647 were more robust than that of the gB/MF59 vaccine, while ADCP responses were lower. Both effector 318 responses have recently been associated with reduced cCMV transmission risk (16, 17). The 319 320 lower ADCP responses elicited by mRNA-1647 vs gB/MF59 vaccine could be attributable to the 321 distinct gB-specific FcR binding (Figure S10) or IgG subclass ratios (Figure 4D-F), but also indicate that PC-specific responses may contribute little to this response. Conversely, the higher 322 ADCC response in mRNA-1647 vs gB/MF59 vaccine indicates that the PC is an important target 323 324 of ADCC.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

325 The expected differences in gB conformation can potentially explain differences in the vaccine-326 elicited functional responses; gB/MF59 vaccine has a truncated transmembrane domain and a mutated furin cleavage site (9), while the mRNA-1647 encodes an intact gB protein (19, 20) that 327 may be expressed in the context of a cell membrane. Yet, the gB AD-specific IgG responses were 328 329 not distinct. One report demonstrated that a Towne ectodomain gB antigen induced better immunogenicity than the full length gB antigen when delivered in the same viral vector (26). 330 Distinct vaccinee populations may also be a confounding factor for comparison between the 331 cohorts, as previously described in immunity elicited by gB/MF59 (9) and natural infection (27). 332 333 The gB/MF59 vaccinees were a lower age range (12-17) than that of mRNA-1647 (18-49) and only female gender, though most vaccinees in the mRNA-1647 cohort were female (76%). 334

335 Durable IgG responses elicited by mRNA-based HCMV vaccine mirrors results of the preclinical 336 models including mice, NHPs (20), and rabbits (30). Yet, it is critical to assess durability at longer 337 intervals given the mRNA-167 vaccine strategy to vaccinate in adolescence for protection against HCMV through reproductive years. Our observation of humoral immune responses lasting over 1 338 year after mRNA-1647 vaccination may stem from long-lived germinal center reactions upon 339 mRNA-LNP vaccination as observed in SARS-CoV2 mRNA-LNP-immunized mice (31) and 340 341 humans (32). Yet, due to sample availability, we were unable to compare response durability with that of gB/MF59 vaccine, which is a limitation of this study. 342

The immune responses required to prevent cCMV transmission may be distinct from those to prevent acquisition. While prevention of mucosal HCMV acquisition may be a challenge, rapid control of viral replication could be effective in eliminating transmission through vaccine-induced Fc-mediated antibody functions such as ADCC (33), ADCP (34) or T cell responses (3). Though T cell responses were not evaluated here, prior studies demonstrated that the mRNA-1647 vaccine is able to elicit potent cell-mediated immunity (20).

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

The advantages of mRNA-LNP vaccine, such as rapid development and flexible re-formulation provide an opportunity to iteratively redesign vaccine immunogens. The impact of the addition of PC and lower magnitude gB-specific IgG responses between the mRNA-1647 and the gB/MF59 vaccine on HCMV acquisition will be informed by the ongoing efficacy trial (NCT05085366), an important benchmark for the HCMV field and the immunogenicity requirements of a successful HCMV vaccine.

355

356 Acknowledgments.

Author Contributions. Investigators were X.H., K.P.K., S.H., S.M.V., J.A.J, H.W., I.G.M., M.C., 357 358 and J.P., E.B.W., K.M.E., D.I.B., and S.R.P. Study design was carried out by X.H., and S.R.P. The trial was managed by J.H., M.K., K. M. E., D.I.B., K.W., A.C. Data analysis and 359 interpretation was carried out by X.H., K.P.K., S.H., S.M.V., J.A.J, H.W., J.P., C.A., L.M.G. and 360 361 S.R.P. Manuscript was drafted by X.H. and edited by K.P.K. and S.R.P. All authors had full access to the presented data, provided critical input during manuscript preparation, and approved 362 the manuscript for submission. We also thank Ms. Carolyn Weinbaum and other members of Dr. 363 Sallie Permar's lab for their support. 364

365 Financial support:

366 This work was supported by Moderna Therapeutics SRA Project# OA22BEA4 and NIH R21

- 367 project # 5R21 AI136556 to S.R.P.
- 368 **Potential conflicts of interest**.

369 S.R.P. is a consultant to Moderna, Merck, Pfizer, GSK, Dynavax, and Hoopika CMV vaccine 370 programs and leads sponsored programs with Moderna and Merck. S.R.P. also serves on the 371 board of the National CMV Foundation and as an educator on CMV for Medscape. E.B.W has

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

- 372 received funding support from Pfizer, Moderna, Sequiris, Najit Technologies Inc, and Clinetic for
- 373 the conduct of clinical trials and clinical research. E.B.W has served as an advisor to Vaxcyte and
- 374 consultant to ILiAD biotechnologies. J.H., M.K., K.W., A.C. has Moderna company' stocks. The
- 375 other authors have no financial conflicts of interest.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

376 **References**:

Boppana SB, Ross SA, Fowler KB. Congenital cytomegalovirus infection: clinical outcome. Clin
 Infect Dis. 2013 Dec;57 Suppl 4:S178-81.

Emery VC. Investigation of CMV disease in immunocompromised patients. J Clin Pathol. 2001
 Feb;54(2):84-8.

Hu X, Wang HY, Otero CE, Jenks JA, Permar SR. Lessons from Acquired Natural Immunity and
 Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development. Annu Rev Virol.
 2022 Sep 29;9(1):491-520.

- Schleiss MR, Permar SR, Plotkin SA. Progress toward Development of a Vaccine against Congenital
 Cytomegalovirus Infection. Clin Vaccine Immunol. 2017 Dec;24(12).
- Shenk TE, Stinski MF. Human cytomegalovirus. Preface. Curr Top Microbiol Immunol. 2008;325:v.
 Isaacson MK, Compton T. Human cytomegalovirus glycoprotein B is required for virus entry and
 cell-to-cell spread but not for virion attachment, assembly, or egress. J Virol. 2009 Apr;83(8):3891-903.
- 389 7. Wang D, Shenk T. Human cytomegalovirus virion protein complex required for epithelial and 390 endothelial cell tropism. Proc Natl Acad Sci U S A. 2005 Dec 13;102(50):18153-8.
- Nelson CS, Baraniak I, Lilleri D, Reeves MB, Griffiths PD, Permar SR. Immune Correlates of
 Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease. J Infect Dis. 2020 Mar
 5;221(Suppl 1):S45-S59.
- Jenks JA, Nelson CS, Roark HK, Goodwin ML, Pass RF, Bernstein DI, et al. Antibody binding to native
 cytomegalovirus glycoprotein B predicts efficacy of the gB/MF59 vaccine in humans. Sci Transl Med. 2020
 Nov 4;12(568).
- 39710.Byrne C, Coombs D, Gantt S. Modestly protective cytomegalovirus vaccination of young children398effectively prevents congenital infection at the population level. Vaccine. 2022 Aug 19;40(35):5179-88.
- 39911.Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, et al. Vaccine prevention of400maternal cytomegalovirus infection. N Engl J Med. 2009 Mar 19;360(12):1191-9.
- 401 12. Bernstein DI, Munoz FM, Callahan ST, Rupp R, Wootton SH, Edwards KM, et al. Safety and efficacy
 402 of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial. Vaccine.
 403 2016 Jan 12;34(3):313-9.
- 13. Nelson CS, Huffman T, Jenks JA, Cisneros de la Rosa E, Xie G, Vandergrift N, et al. HCMV
 glycoprotein B subunit vaccine efficacy mediated by nonneutralizing antibody effector functions. Proc Natl
 Acad Sci U S A. 2018 Jun 12;115(24):6267-72.
- 407 14. Baraniak I, Kropff B, Ambrose L, McIntosh M, McLean GR, Pichon S, et al. Protection from
 408 cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.
 409 Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):6273-8.
- Logo 15. Coppola T, Mangold JF, Cantrell S, Permar SR. Impact of Maternal Immunity on Congenital
 Cytomegalovirus Birth Prevalence and Infant Outcomes: A Systematic Review. Vaccines (Basel). 2019 Sep
 26;7(4).
- 413 16. Semmes EC, Miller IG, Wimberly CE, Phan CT, Jenks JA, Harnois MJ, et al. Maternal Fc-mediated
 414 non-neutralizing antibody responses correlate with protection against congenital human cytomegalovirus
 415 infection. J Clin Invest. 2022 Aug 15;132(16).
- 416 17. Semmes EC, Miller IG, Rodgers N, Phan CT, Hurst JH, Walsh KC, et al. ADCC-activating antibodies
 417 correlate with protection against congenital human cytomegalovirus infection. medRxiv.
 418 2023:2023.03.15.23287332.
- 419 18. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA Vaccine
 420 against SARS-CoV-2 Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920-31.
- 421 19. Ciaramella G, John S, Mousavi K, inventors; HUMAN CYTOMEGALOVIRUS RNA VACCINES. United
 422 States of America patent 10,716,846. 2020 Jul 21.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

20. John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, et al. Multi-antigenic human
cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. Vaccine. 2018
Mar 14;36(12):1689-99.

426 21. Harnois MJ, Dennis M, Stohr D, Valencia SM, Rodgers N, Semmes EC, et al. Characterization of
427 Plasma Immunoglobulin G Responses in Elite Neutralizers of Human Cytomegalovirus. J Infect Dis. 2022
428 Nov 1;226(9):1667-77.

429 22. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial430 cell tropism. J Virol. 2005 Aug;79(16):10330-8.

431 23. Coenon L, Villalba M. From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity
432 Improvement. Front Immunol. 2022;13:913215.

- 433 24. Wen Y, Monroe J, Linton C, Archer J, Beard CW, Barnett SW, et al. Human cytomegalovirus
 434 gH/gL/UL128/UL130/UL131A complex elicits potently neutralizing antibodies in mice. Vaccine. 2014 Jun
 435 24;32(30):3796-804.
- 436 25. Wang H-Y, Taher H, Kreklywich CN, Schmidt KA, Scheef EA, Barfield R, et al. The pentameric 437 complex is not required for vertical transmission of cytomegalovirus in seronegative pregnant rhesus 438 macaques. bioRxiv. 2023:2023.06.15.545169.
- 439 26. Kirchmeier M, Fluckiger AC, Soare C, Bozic J, Ontsouka B, Ahmed T, et al. Enveloped virus-like 440 particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and 441 broad neutralizing activity. Clin Vaccine Immunol. 2014 Feb;21(2):174-80.
- 442 27. Semmes EC, Hurst JH, Walsh KM, Permar SR. Cytomegalovirus as an immunomodulator across the
 443 lifespan. Curr Opin Virol. 2020 Oct;44:112-20.
- 444 28. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-445 correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012 Apr 5;366(14):1275-86.
- Felber BK, Lu Z, Hu X, Valentin A, Rosati M, Remmel CAL, et al. Co-immunization of DNA and
 Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV
 Challenge. Cell Rep. 2020 May 12;31(6):107624.
- 30. Nelson CS, Jenks JA, Pardi N, Goodwin M, Roark H, Edwards W, et al. Human Cytomegalovirus
 Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability
 and Breadth than MF59-Adjuvanted gB Protein Immunization. J Virol. 2020 Apr 16;94(9).
- 452 31. Lederer K, Castano D, Gomez Atria D, Oguin TH, 3rd, Wang S, Manzoni TB, et al. SARS-CoV-2 mRNA
 453 Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing
 454 Antibody Generation. Immunity. 2020 Dec 15;53(6):1281-95 e5.
- 455 32. Lederer K, Bettini E, Parvathaneni K, Painter MM, Agarwal D, Lundgreen KA, et al. Germinal center
 456 responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. Cell. 2022 Mar
 457 17;185(6):1008-24 e15.
- 458 33. Richardson SI, Moore PL. Targeting Fc effector function in vaccine design. Expert Opin Ther 459 Targets. 2021 Jun;25(6):467-77.
- 460 34. Tay MZ, Wiehe K, Pollara J. Antibody-Dependent Cellular Phagocytosis in Antiviral Immune 461 Responses. Front Immunol. 2019;10:332.
- 462 35. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the
 463 BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-15.
- 464 36. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, et al. Safety and 465 Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 Dec 466 17;383(25):2427-38.
- 467

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

468 Table 1: Vaccine participants in the mRNA-1647 vaccine cohort and the timepoints

469 evaluated for humoral responses in current report

Participant	Age	Gender	Serostatus at baseline	Timepoints analyzed for humoral immune responses			
ID	range			Month 0	Month 7	Month 12	Month18
SP-01	16-20	Fa		Ye	Y	Y	Y
SP-02	46-50	М ^ь		Ŷ	Ý	Ý	Ŷ
SP-03	36-40	M	S(+)°	Ý	Ý	Ý	ND
SP-04	41-45	M	(n=6)	Ŷ	Ý	Ý	ND
SP-05	36-40	F	(Ý	Ý	Ý	Ŷ
SP-06	26-30	F		Y	Y	Y	Y
SN-01	41-45	М		Y	Y	Y	ND
SN-02	26-30	F		Y	Y	Y	ND
SN-03	21-25	F		Y	Y	Y	Y
SN-04	36-40	F		Y	Y	Y	Y
SN-05	26-30	Μ		Y	Y	Y	Y
SN-06	41-45	F		Y	Y	Y	Y
SN-07	16-20	Μ		Y	Y	Y	ND
SN-08	21-25	F	C()d	Y	Y	Y	ND
SN-09	31-35	Μ	S(-) ^a	Y	Y	Y	ND
SN-10	21-25	F	(n=17)	Y	Y	Y	ND
SN-11	26-30	F		Y	Y	Y	ND
SN-12	26-30	F		Y	Y	ND ^f	ND
SN-13	46-50	F		Y	Y	Y	ND
SN-14	46-50	F		Y	Y	Y	ND
SN-15	36-40	F		Y	Y	Y	ND
SN-16	41-45	F		Y	Y	ND	Y
SN-17	26-30	F		Y	Y	Y	Y

470

472 S(+)^c: HCMV seropositive at baseline; S(-)^d: HCMV seronegative at baseline

473 Ye :Yes, denotes the sample has been analyzed at this particular timepoint; ND^f: not done due to unavailability of

474 samples;

475

476

477

- 479
- 480

⁴⁷¹ F^a: female; M^b: male;

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

481 Table 2: Comparison of humoral responses in the mRNA-1647 vaccine cohort and gB/MF59

482 vaccine cohort

Humoral Response	mRNA-1647 Seronegative vaccinees (n = 17)	gB/MF59 Seronegative vaccinees (n = 29)	FDR-adjusted
	Median (Range)	Median (Range)	•
IgG binding			
Soluble gB			
gB-specific (Log ₁₀ ED ₅₀)	4.03 (2.82, 4.44)	5.03 (3.78, 5.69)	< 0.001
Avidity (%RAI)	83.00 (65.00, 89.00)	81.91 (68.99, 97.27)	0.402
Virion-specific			
TB40e-specific (Log ₁₀ ED ₅₀)	2.31 (1.48, 2.67)	2.86 (1.85, 3.66)	< 0.001
Avidity (%RAI)	73.10 (56.10, 90.80)	86.72 (63.58, 98.87)	0.001
Cell-associated gB (%binding)			
Towne	1.90 (0.10, 5.70)	6.76 (0.79, 9.33)	< 0.001
Merlin	6.81 (0.71, 12.75)	9.64 (0.54, 19.50)	0.116
gB-specific IgG subclass (Log₁₀MFI)			
lgG1	1.57 (0.00, 2.50)	4.10 (1.09, 4.39)	< 0.001
lgG2	1.41 (0.48, 3.11)	2.22 (0.00, 3.17)	0.094
lgG3	2.96 (0.00, 4.39)	4.18 (2.65, 4.46)	< 0.001
Neutralization (Log ₁₀ ID ₅₀)			
Towne (fibroblast)	2.00 (1.08, 2.34)	1.00 (1.00, 1.37)	< 0.001
AD169r (fibroblast)	1.60 (1.00, 1.87)	1.00 (1.00, 1.06)	< 0.001
AD169r (epithelial)	4.61 (3.26, 5.24)	1.20 (1.00, 2.79)	< 0.001
gB AD mapping (Log₁₀MFI)			
AD-1	1.1 (0.0, 1.7)	1.0 (0.0, 2.4)	0.892
AD-2 site 1 (AUC)	-0.6 (-0.8, 0.5)	-0.5 (-0.7, 0.4)	0.3
AD-4	1.9 (0.0, 3.0)	1.5 (0.0, 2.5)	0.686
AD-5	0.0 (0.0, 1.9)	1.0 (0.0, 2.3)	0.3
AD-4&5	1.6 (0.0, 2.9)	1.7 (0.0, 2.8)	0.686
gB-specific FcR binding (Log₁₀MFI)			
FcRγR1A	3.68 (2.51, 3.98)	3.72 (2.50, 4.10)	0.826
FcRγR2A	3.14 (0.93, 4.14)	4.36 (2.26, 4.40)	< 0.001
FcRγR2B	2.81 (1.20, 3.76)	4.35 (2.10, 4.41)	< 0.001
FcRyR3A	2.58 (1.04, 3.62)	4.27 (2.64, 4.40)	< 0.001
FcRN	2.26 (1.00, 3.72)	3.72 (2.11, 4.39)	< 0.001
Fc-mediated effector functions			
ADCC (% CD107A)	3.20 (0.30, 8.90)	1.60 (0.00, 16.80)	0.032
ADCP (% Phagocytosis)	15.20 (7.80, 30.50)	20.20 (13.10, 47.10)	< 0.001

483 p<0.05 (bolded) is considered significant. Underlined values represent significantly higher responses.

484 FDR: False discovery rate, RAI: Relative Avidity Index, MFI: Mean Fluorescent Intensity.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

485 **Figure Legends**

486 Figure 1. mRNA-1647 vaccine-induced long-lasting antigen-specific IgG antibody

487 responses in HCMV seropositive and seronegative vaccinees.

(A) The immunization schedule for HCMV mRNA-1647 vaccine candidate with doses 488 administrated at months 0, 2, and 6 for both HCMV seropositive (N=6) and seronegative 489 (N=17) vaccine recipients. The soluble gB-specific, PC-specific, and TB40/E virion-bound 490 IgG antibody titers (ED50: effective dose 50) were determined via ELISA for both 491 seropositive (B, D, F) and seropositive (C, E, G) vaccinees, respectively, at the indicated 492 time points including the 1-year follow-up after last vaccination. The dotted line indicates 493 the limit of detection (ED50=30). IgG binding activities to Merlin gB-transfected cells were 494 evaluated for seronegative (H) and seropositive (I) vaccinees at the indicated time points 495 via flow cytometry-based assay. p values from Wilcoxon matched-pairs signed rank test 496 are reported. *p<0.05, **p<0.01, ***p<0.001. 497

498 Figure 2 Durable neutralizing antibody responses elicited by the mRNA-1647 vaccine in 499 both seropositive and seronegative vaccine recipients.

Fibroblast neutralization reactivities against Towne virus in HFF-1 cells were compared before (month 0) and after (month7) vaccination for both seronegative (A) and seropositive (B) vaccinees. Similarly, fibroblast neutralization responses against AD169r virus in HFF-1 cells and epithelial neutralization antibody responses against AD169 in ARPE-19 cells were monitored before vaccination (month 0), month 7, 12 to 18 after vaccination for both seronegative (C, E) and seropositive (D, F) vaccinees, respectively, to assess durability. p values from Wilcoxon matched pairs signed rank test are reported. *p<0.05, **p<0.01, ***p<0.001.

507 Figure 3. FcRs binding magnitude and IgG Fc-portion mediated functionalities induced by

508 the mRNA-1647 vaccine in both seropositive and seronegative vaccinees.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

gB-specific (A) and PC-specific (B) IgG Fc antibody (FcyR1A, FcyR2A (H131), FcyR2B, FcyR3A 509 (V158), and FcRN) responses were plotted for both seronegative and seropositive vaccinees 510 511 before vaccination (month 0) and at the peak time point (month 7). Vaccine-induced IgG antibody 512 Fc-mediated AD169r virion ADCC (C) and ADCP (D) responses were assessed for both seronegative and seropositive vaccinees. p values from Wilcoxon matched-pairs signed rank test 513 are reported. Spearman correlation analysis between AD169r virion ADCC (E) and ADCP (G) 514 515 responses and gB-specific and PC-specific IgG FcR binding magnitude with the spearman r value 516 shown for seronegative only (S(-)) and all vaccinees (ALL) is reported. Correlation for ADCC and gB-specific FcR binding magnitude (F), ADCP and gB-specific (H) FcR binding magnitude for 517 518 seronegative only (S(-)) and all vaccinees (ALL) is reported; S-: seronegative samples; ALL 519 include seronegative (open diamond symbol) and seropositive samples (open circle symbol)). *p<0.05, **p<0.01, ***p<0.001. 520

521 Figure 4. mRNA-1647 induced higher PC-specific IgG responses than gB-specific 522 responses in the same formulation

The magnitude of mRNA-1647 vaccine-induced total IgG responses and IgG subclass (IgG1, 523 524 IgG2 and IgG3) responses were compared between gB-specific and PC-specific responses for both seronegative (A-D) and seropositive (E-H) vaccinees at month 7. The total IgG responses 525 526 were measured by ELISA, while the IgG subclass (IgG1, IgG2, and IgG3) responses were 527 detected via BAMA. p values from Wilcoxon matched pairs signed rank test are reported. The level of IaG Fc antibody responses (FcyR1A, FcyR2A, FcyR2B, FcyR3A, and FcRN) were 528 529 compared among gB and PC antigen components in the same vaccine formulation in both 530 seronegative (I-M) and seropositive (N-R) vaccinees in mRNA-1647 vaccine cohort. p values from non-parametric t-tests are reported (Mann-Whitney). *p<0.05, **p<0.01, ***p<0.001. 531

Figure 5. Comparison of gB-specific peak IgG binding antibody and neutralizing antibody responses.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft

534 (A): Cartoons illustrating the immunization schedules for mRNA-1647 and gB/MF59 vaccine 535 cohorts for vaccine-induced gB-specific antibody peak responses comparison at month 7. Soluble gB-specific total IgG antibody titers (B) relative avidity index (RAI) (C) and IgG subclass IgG1 (D). 536 IgG2 (E), and IgG3 (F) responses were compared between the two vaccine cohorts. TB40/E 537 538 virion-bound IgG titers (G) and RAI (H) were also compared between the two vaccine cohorts. Similarly, Towne qB (I) and Merlin qB (J) cell-associated IqG antibody responses were compared 539 among the two vaccine cohorts. The epithelial neutralizing antibody against AD169r (K) in ARPE-540 541 19 cells and fibroblast neutralizing antibody against AD169r (L) and against Towne (M) in HFF-1 542 cells were compared between mRNA-1647 and gB/MF59 vaccine cohorts. Additionally, the HCMV infected individuals were also included for the comparison. Open blue circle denotes the 543 seropositive samples at baseline from the mRNA-1647 vaccine cohort while open purple circle 544 denotes the in-house HCMV seropositive subjects in some assays to increase the statistical 545 546 power. But the statistical analysis indicated the increased sample # didn't change the conclusion. *p<0.05, **p<0.01. P values from non-parametric t-tests are reported (Mann-Whitney). 547 ***p<0.001. 548

549 **Figure 6. gB/MF59 vaccine elicited higher peak FcRs and ADCP but lower ADCC functional** 550 **antibody responses than the mRNA-1647 vaccine candidate.**

551 gB-specific FcyR1A (A), 2A (B), 2B (C), 3A (D), and FcRN (E) antibody responses were compared 552 between the two vaccine cohorts indicative of overall higher-level responses except for FcgR1A response in the gB/MF59 vaccine cohort; AD169r virion ADCC (F) and ADCP (G) effector 553 antibody responses were compared between two vaccine cohorts suggesting elevated ADCC 554 responses, but lower ADCP responses were found in mRNA-1647 cohort. Additionally, the HCMV 555 556 infected individuals were also included in the comparison. Open blue circle denotes the 557 seropositive samples at baseline from the mRNA-1647 vaccine. p values from non-parametric ttests are reported (Mann-Whitney). *p<0.05, **p<0.01, ***p<0.001. 558

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft





(A) The immunization schedule for HCMV mRNA-1647 vaccine candidate with doses administrated at months 0, 2, and 6 for both HCMV seropositive (N=6) and seronegative (N=17) vaccine recipients. The soluble gB-specific, PC-specific, and TB40/E virion-bound IgG antibody titers (ED50: effective dose 50) were determined via ELISA for both seropositive (B, D, F) and seropositive (C, E, G) vaccinees, respectively, at the indicated time points including the 1-year follow-up after last vaccination. The dotted line indicates the limit of detection (ED50=30). IgG binding activities to Merlin gB-transfected cells were evaluated for seronegative (H) and seropositive (I) vaccinees at the indicated time points via flow cytometry-based assay. p values from Wilcoxon matched-pairs signed rank test are reported. *p<0.05, **p<0.01, ***p<0.001.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript submissiondraft



Figure 2

Figure 2 Durable neutralizing antibody responses elicited by the mRNA-1647 vaccine in both seropositive and seronegative vaccine recipients.

Fibroblast neutralization reactivities against Towne virus in HFF-1 cells were compared before (month 0) and after (month7) vaccination for both seronegative (A) and seropositive (B) vaccinees. Similarly, fibroblast neutralization responses against AD169r virus in HFF-1 cells and epithelial neutralization antibody responses against AD169 in ARPE cells were monitored before vaccination (month 0), month 7, 12 to 18 after vaccination for both seronegative (C, E) and seropositive (D, F) vaccinees, respectively, to assess durability. p values from Wilcoxon matched pairs signed rank test are reported. *p<0.05, **p<0.01, ***p<0.001.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript submissiondraft





gB-specific (A) and PC-specific (B) IgG Fc antibody (FcrR1A, FcrR2A (H131), FcrR2B, FcrR3A (V158), and FcRN) responses were plotted for both seronegative and seropositive vaccinees before vaccination (month 0) and at the peak time point (month 7). Vaccine-induced IgG antibody Fc-mediated AD169 virion ADCC (C) and ADCP (D) responses were assessed for both seronegative and seropositive vaccinees. p values from Wilcoxon matched-pairs signed rank test are reported. Speaman correlation analysis between AD169 virion ADCC (E) and ADCP (G) responses and gB-specific and PC-specific IgG FcR binding magnitude with the speaman r value shown for seronegative only (S(-)) and all vaccinees (ALL) is reported. Correlation for ADCC and gB-specific (H) FcR binding magnitude for seronegative only (S(-)) and all vaccinees (ALL) is reported. (S(-)) and all vaccinees (ALL) is reported; Seronegative samples; ALL include seronegative (open diamond symbol) and seropositive samples (open dicle symbol)). *p<0.05, **p<0.01, ***p<0.001.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft



Figure 4. mRNA-1647 induced higher PC-specific IgG responses than gB-specific responses in the same formulation. The magnitude of mRNA-1647 vaccine-induced total IgG responses and IgG subclass (IgG1, IgG2 and IgG3) responses were compared between gB-specific and PC-specific responses for both seronegative (A-D) and seropositive (E-H) vaccinees at month 7. The total IgG responses were measured by ELISA, while the IgG subclass (IgG1, IgG2, and IgG3) responses were detected via BAMA. p values from Wilcoxon matched pairs signed rank test are reported. The level of IgG Fc antibody responses (Fcr/R1A, Fcr/R2A, Fcr/R2B, Fcr/R3A, and FcRN) were compared among gB and PC antigen components in the same vaccine formulation in both seronegative (I-M) and seropositive (N-R) vaccinees in mRNA-1647 vaccine cohort. p values from non-parametrict-tests are reported (Mann-Whitney). *p<0.05, **p<0.01, ***p<0.001.

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft



Figure 5. Comparison of gB-specific peak IgG binding antibody and neutralizing antibody responses.

(A): Cartoons illustrating the immunization schedules for mRNA-1647 and gB/MF59 vaccine cohorts for vaccine-induced gB-specific antibody responses comparison. Soluble gB-specific total IgG antibody titers (B) relative avidity index (RAI) (C) and IgG subclass IgG1 (D), IgG2 (E), and IgG3 (F) responses were compared between the two vaccine cohorts. TB40/E virion-bound IgG titers (G) and RAI (H) were also compared between the two vaccine cohorts. Similarly, Towne gB cell-associated (I) and Merlin gB cell-associated IgG antibody responses were compared among the two vaccine cohorts. The epithelial neutralizing antibody against AD169r (K) in ARPE cells and fibroblast neutralizing antibody against AD169r (L) and against Towne (M) in HFF cells were compared between mRNA-1647 and gB/MF59 vaccine cohorts. Additionally, 5the HCMV infected individuals were also included for the comparison. Open purple circle denotes the in-house HCMV seropositive subjects. P values from non-parametric t-tests are reported (Mann-Whitney). *p<0.05, **p<0.01.</p>

Broad and Functional anti-HCMV IgG responses induced by mRNA-1647manuscript_submissiondraft



Figure 6. gB/MF59 vaccine elicited higher peak FcRs and ADCP but lower ADCC functional antibody responses than the mRNA-1647 vaccine candidate.

(A) gB-specific FcγR1A (A), 2A (B), 2B (C), 3A (D), and FcRN (E) antibody responses were compared between the two vaccine cohorts indicative of overall higher-level responses except for FcgR1A response in the gB/MF59 vaccine cohort; AD169 virion ADCC (F) and ADCP (G) effector antibody responses were compared between two vaccine cohorts suggesting elevated ADCC responses, but lower ADCP responses were found in mRNA-1647 cohort. Additionally, the HCMV infected individuals were also included in the comparison. p values from non-parametric t-tests are reported (Mann-Whitney). *p<0.05, **p<0.01, ***p<0.001.